A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy.

Trial Profile

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OAK
  • Sponsors Roche
  • Most Recent Events

    • 21 Jul 2017 According to a Roche media release, The EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ (atezolizumab) as a monotherapy. People with EGFR activating mutations or ALK positive tumour mutations should also have received targeted therapy before receiving TECENTRIQ. This positive recommendation is based on results from the OAK study and the POPLAR study.
    • 27 Jun 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2018.
    • 02 Jun 2017 Results (n=332) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top